<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05105438</url>
  </required_header>
  <id_info>
    <org_study_id>CAPS_CH</org_study_id>
    <nct_id>NCT05105438</nct_id>
  </id_info>
  <brief_title>Alternate Day vs. Daily Iron Supplementation in Iron Depleted Women</brief_title>
  <official_title>Comparing Oral Iron Supplementation Using Alternate-day Dosing to the Standard of Care Consecutive-day Dosing in Iron-depleted Women With or Without Mild Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Federal Institute of Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swiss Federal Institute of Technology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Iron deficiency (ID) with or without anemia is a major public health problem worldwide,&#xD;
      especially in women of reproductive age. Iron supplementation can be an effective strategy to&#xD;
      prevent and treat ID and iron deficiency anemia (IDA). Recent studies suggests that giving&#xD;
      oral iron every other day would be an optimized dosing regimen with maximized absorption and&#xD;
      a lower incidence of gastrointestinal side effects compared to consecutive day dosing.&#xD;
      Long-term trials in which participants and investigators are blinded to the dosing interval&#xD;
      with iron status and gastrointestinal side effects as study outcomes are needed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>double-blinded randomized controlled study: participants and investigators are blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Ferritin (SF)</measure>
    <time_frame>Day 93</time_frame>
    <description>in consecutive day group</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Ferritin (SF)</measure>
    <time_frame>Day 186</time_frame>
    <description>in alternate day group</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Event rate of GI side effects</measure>
    <time_frame>Day 90</time_frame>
    <description>in consecutive day group</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Event rate of GI side effects</measure>
    <time_frame>Day 183</time_frame>
    <description>in alternate day group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin (Hb)</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin (Hb)</measure>
    <time_frame>Day 46</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin (Hb)</measure>
    <time_frame>Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin (Hb)</measure>
    <time_frame>Day 139</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin (Hb)</measure>
    <time_frame>Day 183</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Ferritin (SF)</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Ferritin (SF)</measure>
    <time_frame>Day 46</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Ferritin (SF)</measure>
    <time_frame>Day 93</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Ferritin (SF)</measure>
    <time_frame>Day 139</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Ferritin (SF)</measure>
    <time_frame>Day 186</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Transferrin Receptor (sTfR)</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Transferrin Receptor (sTfR)</measure>
    <time_frame>Day 46</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Transferrin Receptor (sTfR)</measure>
    <time_frame>Day 93</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Transferrin Receptor (sTfR)</measure>
    <time_frame>Day 139</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Transferrin Receptor (sTfR)</measure>
    <time_frame>Day 186</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total iron binding capacity (TIBC)</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total iron binding capacity (TIBC)</measure>
    <time_frame>Day 93</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total iron binding capacity (TIBC)</measure>
    <time_frame>Day 186</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Iron (SFe)</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Iron (SFe)</measure>
    <time_frame>Day 93</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Iron (SFe)</measure>
    <time_frame>Day 186</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-Reactive Protein (CRP)</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-Reactive Protein (CRP)</measure>
    <time_frame>Day 46</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-Reactive Protein (CRP)</measure>
    <time_frame>Day 93</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-Reactive Protein (CRP)</measure>
    <time_frame>Day 139</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-Reactive Protein (CRP)</measure>
    <time_frame>Day 186</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alpha-1-acid Glycoprotein (AGP)</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alpha-1-acid Glycoprotein (AGP)</measure>
    <time_frame>Day 46</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alpha-1-acid Glycoprotein (AGP)</measure>
    <time_frame>Day 93</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alpha-1-acid Glycoprotein (AGP)</measure>
    <time_frame>Day 139</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alpha-1-acid Glycoprotein (AGP)</measure>
    <time_frame>Day 186</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intestinal Fatty Acid-binding Protein (I-FABP)</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intestinal Fatty Acid-binding Protein (I-FABP)</measure>
    <time_frame>Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intestinal Fatty Acid-binding Protein (I-FABP)</measure>
    <time_frame>Day 183</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calprotectin</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calprotectin</measure>
    <time_frame>Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calprotectin</measure>
    <time_frame>Day 183</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepcidin</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepcidin</measure>
    <time_frame>Day 46</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepcidin</measure>
    <time_frame>Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepcidin</measure>
    <time_frame>Day 139</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepcidin</measure>
    <time_frame>Day 183</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event rate of GI side effects</measure>
    <time_frame>Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event rate of GI side effects</measure>
    <time_frame>Day 183</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of GI side effects</measure>
    <time_frame>Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of GI side effects</measure>
    <time_frame>Day 183</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event proportion of GI side effects</measure>
    <time_frame>Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event proportion of GI side effects</measure>
    <time_frame>Day 183</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of GI side effects</measure>
    <time_frame>Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of GI side effects</measure>
    <time_frame>Day 183</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal blood losses</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal blood losses</measure>
    <time_frame>Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal blood losses</measure>
    <time_frame>Day 183</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Iron absorption from supplements</measure>
    <time_frame>Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Iron absorption from supplements</measure>
    <time_frame>Day 183</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Iron-deficiency</condition>
  <condition>Iron Deficiency Anemia</condition>
  <arm_group>
    <arm_group_label>Consecutive Day Dosing</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>100 mg iron as FeSO4 daily for 3 months, followed by matched placebo daily for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alternate Day Dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg iron as FeSO4 and matched placebo on alternating days for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Consecutive Day Dosing</intervention_name>
    <description>100 mg iron as FeSO4 daily for 3 months, followed by matched placebo daily for 3 months.</description>
    <arm_group_label>Consecutive Day Dosing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Alternate Day Dosing</intervention_name>
    <description>100 mg iron as FeSO4 and matched placebo on alternating days for 6 months.</description>
    <arm_group_label>Alternate Day Dosing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female, 18 to 45 years old,&#xD;
&#xD;
          -  SF levels &lt;25 μg/L,&#xD;
&#xD;
          -  Hb levels ≥ 11 g/dL&#xD;
&#xD;
          -  Normal Body Mass Index (18.5-25 kg/m2),&#xD;
&#xD;
          -  In possession of a mobile phone on which the study app can be loaded,&#xD;
&#xD;
          -  Signed informed consent,&#xD;
&#xD;
          -  Not mandatory (only for subgroup analysis): having participated in a former stable&#xD;
             iron isotope study in our laboratory between 1-5 y ago&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Elevated CRP &gt; 5 mg/L,&#xD;
&#xD;
          -  Any metabolic, gastrointestinal, kidney or chronic disease (self-reported) affecting&#xD;
             iron metabolism,&#xD;
&#xD;
          -  Continuous/long-term use of medication, which may interfere with iron absorption, gut&#xD;
             physiology and iron metabolism,&#xD;
&#xD;
          -  Consumption of additional iron supplements over the study period,&#xD;
&#xD;
          -  Consumption of iron supplements since screening,&#xD;
&#xD;
          -  Difficulties with blood sampling,&#xD;
&#xD;
          -  Known hypersensitivity or allergy to iron or placebo capsules in the given amount&#xD;
             (ferrous sulfate, mannitol, silica)&#xD;
&#xD;
          -  Pregnancy, breastfeeding&#xD;
&#xD;
          -  Women who intend to become pregnant during the course of the study,&#xD;
&#xD;
          -  Known or suspected non-compliance, drug or alcohol (more than 2 drinks/day) abuse,&#xD;
&#xD;
          -  Smokers (&gt; 1 cigarette per week),&#xD;
&#xD;
          -  Participant is likely to be absent on one the study appointments,&#xD;
&#xD;
          -  Inability to follow the procedures of the study, e.g. due to language problems,&#xD;
             self-reported psychological disorders, etc. of the participant.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>women</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicole Stoffel, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Human Nutrition Laboratory, ETH Zuerich</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hanna von Siebenthal, MSc</last_name>
    <phone>+41 44 632 53 73</phone>
    <email>hanna.vonsiebenthal@hest.ethz.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nicole Stoffel, PhD</last_name>
    <phone>+41 44 632 83 93</phone>
    <email>nicole.stoffel@hest.ethz.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ETH Zurich; Human Nutrition Laboratory; Institute of Food, Nutrition and Health</name>
      <address>
        <city>Zürich</city>
        <zip>8092</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Hanna von Siebenthal, MSc</last_name>
      <phone>+41 44 632 53 73</phone>
      <email>hanna.vonsiebenthal@hest.ethz.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 22, 2021</study_first_submitted>
  <study_first_submitted_qc>October 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2021</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Swiss Federal Institute of Technology</investigator_affiliation>
    <investigator_full_name>Nicole Stoffel</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>iron supplementation</keyword>
  <keyword>dosing regimen</keyword>
  <keyword>iron sulfate</keyword>
  <keyword>women of reproductive age</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

